UMaine med device spinoff Neuright receives $225K tech transfer award

Neuright Inc., a University of Maine biotech spinoff focused on the early diagnosis and treatment of peripheral neuropathy, was awarded $225,000 under the National Science Foundation’s Small Business Technology Transfer program to develop its technology for delivery to market.

Peripheral neuropathy, a condition in which nerve fibers die back from the skin, is estimated to affect more than 20 million people in the U.S. and can cause symptoms including pain, numbness and loss of limb control, according to a news release.

Diabetes is the leading cause of peripheral neuropathy. Up to 70% of the 34 million Americans with diabetes will also have peripheral neuropathy. Wide-ranging, variable symptoms make peripheral neuropathy difficult to diagnose, and while there is no cure, early intervention and treatment can help patients minimize the often-debilitating effects. Read more

Related Posts

Maine’s startup ‘mojo’ highlighted in national ranking

As a place to start a business, Maine’s “mojo” is going strong, as shown in a new national ranking released Tuesday by WalletHub,...

19 January 2023

Maine CDC Director Nirav Shah to join U.S. CDC leadership

Dr. Nirav Shah, director of the Maine Center for Disease Control and Prevention, has been appointed principal deputy director at the...

13 January 2023

$5.6M in state funding to support Maine startups, entrepreneurs

Sixteen Maine organizations helping startups and entrepreneurs will share $5.6 million in state funding from the Pandemic Recovery for an Innovative Maine...

11 January 2023